Epizyme, Inc. (EPZM) Shares Bought by Alps Advisors Inc.

Alps Advisors Inc. boosted its position in Epizyme, Inc. (NASDAQ:EPZM) by 9.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,472 shares of the biopharmaceutical company’s stock after buying an additional 4,797 shares during the quarter. Alps Advisors Inc. owned approximately 0.08% of Epizyme worth $1,095,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. NEA Management Company LLC increased its holdings in Epizyme by 3.2% in the third quarter. NEA Management Company LLC now owns 6,460,851 shares of the biopharmaceutical company’s stock valued at $123,079,000 after buying an additional 200,000 shares during the last quarter. Palo Alto Investors LLC increased its holdings in Epizyme by 18.9% in the second quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock valued at $86,044,000 after buying an additional 907,245 shares during the last quarter. Vanguard Group Inc. increased its holdings in Epizyme by 6.2% in the second quarter. Vanguard Group Inc. now owns 3,419,844 shares of the biopharmaceutical company’s stock valued at $51,640,000 after buying an additional 200,982 shares during the last quarter. State Street Corp increased its holdings in Epizyme by 59.6% in the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock valued at $26,644,000 after buying an additional 658,727 shares during the last quarter. Finally, Lord Abbett & CO. LLC bought a new stake in Epizyme in the second quarter valued at about $9,726,000. 70.95% of the stock is owned by hedge funds and other institutional investors.

EPZM has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a report on Monday, August 7th. Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the company a “buy” rating in a report on Saturday, August 5th. Jefferies Group LLC initiated coverage on Epizyme in a report on Wednesday, September 20th. They set a “buy” rating and a $23.00 target price for the company. Oppenheimer Holdings, Inc. reissued a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a report on Tuesday, September 19th. Finally, Cann reissued a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a report on Tuesday, September 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $22.67.

Shares of Epizyme, Inc. (NASDAQ:EPZM) opened at $13.65 on Tuesday. Epizyme, Inc. has a 52-week low of $9.30 and a 52-week high of $20.45.

Epizyme (NASDAQ:EPZM) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.02. equities analysts anticipate that Epizyme, Inc. will post -2.23 EPS for the current fiscal year.

WARNING: “Epizyme, Inc. (EPZM) Shares Bought by Alps Advisors Inc.” was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/11/14/epizyme-inc-epzm-shares-bought-by-alps-advisors-inc.html.

In other news, Director David M. Mott bought 200,000 shares of the business’s stock in a transaction on Monday, September 18th. The stock was purchased at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the completion of the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $91,500. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 24th. The stock was sold at an average price of $16.44, for a total value of $246,600.00. Following the completion of the sale, the insider now owns 23,123 shares of the company’s stock, valued at $380,142.12. The disclosure for this sale can be found here. Insiders sold 45,000 shares of company stock valued at $733,950 over the last 90 days. 25.20% of the stock is currently owned by insiders.

Epizyme Profile

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply